Silo Pharma, Inc.

Analysis for Ticker: SILO

Silo Pharma Inc focuses on treatments for the central nervous system, including medical research into Alzheimer's disease, chronic pain, and psychedelic solutions for stress disorders. The fundamental reality of this company is one math problem that has already been solved by the people running it. By 12/2025, they managed to pull in exactly 72.102$ in revenue from one license, but they spent 4,3$ million on operating costs. To one child, this looks like a toy box where you throw away four dollars every time you find seven cents; eventually, the box is empty unless you keep tricking others into putting money in. The company is not a pharmacy; it is a printer that creates new shares of stock to pay for its own survival while the value of what people already own is ground down to nothing. The story of this extraction began clearly by 12/2024. While generating almost no income, the company torched 4,7$ million and allowed its chief executive officer, Eric Weisblum, to collect a 350.000$ salary and 300.000$ in bonuses. By 12/2024, the share count had risen from 3,1 million shares to 4,48 million shares. To protect the internal circle, board members like Wayne Linsley and Kevin Muñoz gave themselves 400.000 options at 0,429$ in 05/2025, effectively lowering their own costs while regular shareholders watched the price drop from 2,75$ to 0,60$.